Berlin, Germany, June 4, 2019. Last week, a collaboration agreement between Ramaiah Medical College Hospitals and Eckert & Ziegler BEBIG was signed in order to enhance awareness, education and products in the field of brachytherapy.
The collaboration will focus on HDR brachytherapy with Ramaiah Medical College Hospitals as an experienced provider of gynecological, head and neck, breast, and lung cancer treatments. The healthcare provider has been a user of the MultiSource afterloader for years and will upgrade to using a SagiNova® afterloader within the coming weeks. Moreover, Ramaiah Medical College Hospitals will introduce prostate brachytherapy to its treatment portfolio. “Prostate cancer, when detected early, is well treatable with brachytherapy. Therefore, with about 25,000 new cases in 2018, the number of deaths of about 17,000 is far too high*. One of our aims is to raise awareness of prostate cancer diagnosis and treatment options to contribute to lowering the number of annual deaths”, states Dr. Janaki M.G., Professor and Head of the Radiation Oncology Department.
The introduction of a reference center in India, effective as of June 2019, is part of the commitment that Eckert & Ziegler BEBIG is placing in the country. Since the first MultiSource afterloader that entered into operation in the country in 2007, the number of devices - MultiSource and later, SagiNova® - has risen continuously. In India, Eckert & Ziegler BEBIG is well known for its expertise in cobalt-60 sources, which are available for the company´s HDR afterloaders. With a proven record of running and clinically-used cobalt-60 systems in India and almost 50 other countries, Eckert & Ziegler BEBIG has established itself as the leading provider for this source type. Due to the long half-life of cobalt-60, the source can be used for up to 5 years, which means that, during the recommended working life of a single cobalt-60 source, approximately 20 source exchanges of iridium-192 would have to be performed. The significant time saved in performing quality assurance checks after each source exchange makes the use of cobalt-60 particuarly attractive for India´s high-volume clinics. Addionally, cobalt-60 is the isotope of choice for countries with demanding logistics.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Germany, with production facilities in Germany and in the USA, as well as offices throughout Europe, Asia and the USA. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 145 people.
Marketing Communication Manager